Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?
Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.
You may also be interested in...
House and Senate release discussion draft of user fee reauthorization legislation that does not include any additional policy or practice changes for US FDA, though they may arrive later.
Latest Office of Management and Budget directive lifts the pause on federal hiring, but requires US FDA and others to develop long-term plans to cut staff.
US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.